MBB Public Markets I LLC Makes New Investment in Gilead Sciences, Inc. $GILD

Key Points

• MBB Public Markets I LLC has invested approximately $340,000 in Gilead Sciences by acquiring 3,037 shares in the 1st quarter.
• Insider trading activity was noted, with CEO Daniel Patrick O'day selling 10,000 shares worth $1,136,300, resulting in a 1.65% decrease in his ownership.
• Gilead Sciences reported a quarterly earnings per share of $2.01, exceeding analysts' expectations, and providing FY 2025 guidance of $7.950-8.250 EPS.

MBB Public Markets I LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,037 shares of the biopharmaceutical company's stock, valued at approximately $340,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nissay Asset Management Corp Japan ADV raised its position in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares in the last quarter. Ariel Investments LLC raised its position in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares in the last quarter. Mufg Securities Americas Inc. bought a new position in shares of Gilead Sciences in the 4th quarter worth $1,699,000. Finally, ASR Vermogensbeheer N.V. bought a new position in shares of Gilead Sciences in the 1st quarter worth $11,688,000. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,371,330 over the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 2.8%

NASDAQ:GILD traded down $3.31 during mid-day trading on Friday, hitting $114.55. 6,466,956 shares of the company's stock traded hands, compared to its average volume of 5,830,447. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a fifty day moving average of $114.04 and a 200 day moving average of $110.09. The company has a market capitalization of $142.13 billion, a P/E ratio of 22.82, a P/E/G ratio of 0.80 and a beta of 0.36. Gilead Sciences, Inc. has a twelve month low of $81.57 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.